Interius BioTherapeutics Overview
- Year Founded
-
2019
- Status
-
Acquired/Merged
- Employees
-
19
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$350M
Interius BioTherapeutics General Information
Description
Developer of a genetic medicines precision delivery platform intended to treat hematologic malignancies. The company's platform develops chimeric antigen receptor T cells directly in vivo, bypassing the need for ex vivo cell manipulations and the potentially toxic preconditioning chemotherapy required for standard CAR T-cell treatments, enabling clinicians to provide therapies to treat an array of challenging diseases for patients.
Contact Information
Website
www.interiusbio.comCorporate Office
- 3401 Grays Ferry Avenue
- Building 200, Suite 300
- Philadelphia, PA 19146
- United States
Corporate Office
- 3401 Grays Ferry Avenue
- Building 200, Suite 300
- Philadelphia, PA 19146
- United States
Interius BioTherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Merger/Acquisition | 14-Oct-2025 | $350M | Completed | Clinical Trials - Phase 1 | ||
| 6. Later Stage VC (Series C) | 27-Feb-2025 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC (Series B) | 03-Jun-2024 | Completed | Pre-Clinical Trials | |||
| 4. Accelerator/Incubator | Completed | Pre-Clinical Trials | ||||
| 3. Early Stage VC (Series A) | 18-May-2021 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 05-Aug-2020 | $1.57M | $1.57M | Completed | Pre-Clinical Trials | |
| 1. University Spin-Out | 01-Jan-2019 | Completed | Startup |
Interius BioTherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A | 29,537,258 | $0.000100 | 6% | $2.58 | $2.58 | 1x | $2.58 | 18.51% |
| Seed | 11,458,300 | $0.000100 | 6% | $0.48 | $0.48 | 1x | $0.48 | 7.18% |
Interius BioTherapeutics Comparisons
Industry
Financing
Details
Interius BioTherapeutics Competitors (5)
One of Interius BioTherapeutics’s 5 competitors is Athos Therapeutics, a Venture Capital-Backed company based in Los Angeles, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Athos Therapeutics | Venture Capital-Backed | Los Angeles, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Autolus | Formerly VC-backed | London, United Kingdom | ||||
| Regenxbio | Formerly VC-backed | Rockville, MD | ||||
| Jubilant Therapeutics | Corporation | Allentown, PA |
Interius BioTherapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Interius BioTherapeutics Patents
Interius BioTherapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026030432-A1 | Processes for the purification of viral particles and formulations thereof | Pending | 31-Jul-2024 | ||
| AU-2025270872-A1 | Infectious titration assay | Pending | 08-May-2024 | ||
| WO-2025235727-A1 | Infectious titration assay | Pending | 08-May-2024 | ||
| AU-2025267806-A1 | Methods of detecting residual dna in viral preparations | Pending | 08-May-2024 | ||
| WO-2025235738-A1 | Methods of detecting residual dna in viral preparations | Pending | 08-May-2024 | C12N15/86 |
Interius BioTherapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Interius BioTherapeutics Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ACS BrightEdge | Corporate Venture Capital | Minority | ||
| Agent Capital | Venture Capital | Minority | ||
| Bain Capital Life Sciences | Corporate Venture Capital | Minority | ||
| Cormorant Asset Management | PE/Buyout | Minority | ||
| DC Investment Partners | Venture Capital | Minority |
Interius BioTherapeutics FAQs
-
When was Interius BioTherapeutics founded?
Interius BioTherapeutics was founded in 2019.
-
Where is Interius BioTherapeutics headquartered?
Interius BioTherapeutics is headquartered in Philadelphia, PA.
-
What is the size of Interius BioTherapeutics?
Interius BioTherapeutics has 19 total employees.
-
What industry is Interius BioTherapeutics in?
Interius BioTherapeutics’s primary industry is Drug Delivery.
-
Is Interius BioTherapeutics a private or public company?
Interius BioTherapeutics is a Private company.
-
What is the current valuation of Interius BioTherapeutics?
The current valuation of Interius BioTherapeutics is .
-
What is Interius BioTherapeutics’s current revenue?
The current revenue for Interius BioTherapeutics is .
-
How much funding has Interius BioTherapeutics raised over time?
Interius BioTherapeutics has raised $170M.
-
Who are Interius BioTherapeutics’s investors?
ACS BrightEdge, Agent Capital, Bain Capital Life Sciences, Cormorant Asset Management, and DC Investment Partners are 5 of 19 investors who have invested in Interius BioTherapeutics.
-
Who are Interius BioTherapeutics’s competitors?
Athos Therapeutics, Kite Pharma, Autolus, Regenxbio, and Jubilant Therapeutics are competitors of Interius BioTherapeutics.
-
When was Interius BioTherapeutics acquired?
Interius BioTherapeutics was acquired on 14-Oct-2025.
-
Who acquired Interius BioTherapeutics?
Interius BioTherapeutics was acquired by Kite Pharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
